Boat line thousands of miles set in the anchor, the waves lift stable in the heart

Type 2 diabetes is a chronic metabolic disease characterized by elevated blood sugar levels due to insulin resistance and insufficient insulin secretion. The disease is more common in adults, but can also affect children and adolescents. At present, the prevalence of diabetes is on the rise. According to the World Health Organization (WHO), the number of people with type 2 diabetes worldwide has exceeded 463 million by 2020. This number has continued to grow over the past few decades, mainly due to an aging population, rising obesity rates, and unhealthy lifestyles such as physical inactivity and poor diet. According to the International Diabetes Federation (IDF), type 2 diabetes accounts for more than 90% of all diabetes cases and has become a serious public health problem in many countries and regions. Diabetes is also a leading cause of blindness, kidney failure, heart attack, stroke and lower limb amputation, and was responsible for an estimated 2 million deaths in 2019.

Currently, drugs used to treat type 2 diabetes include metformin, which reduces glucose output from the liver, GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and alpha-glucosidase inhibitors. However, most drugs can only control blood sugar levels, not cure diabetes. And these drugs have a variety of side effects, such as low blood sugar, kidney damage or cardiovascular risks. Long-term use may also lead to drug failure or accumulation of side effects. Therefore, the development of safer and more effective treatment means or drugs has become an urgent clinical need.

Scientists at Lisanobiology identified a subgroup of type 2 diabetes during a six-year cohort follow-up study of the Human Microbiome Project Phase II (iHMP), launched in 2013. Insulin resistance in this subgroup of patients is caused by the disturbance of intestinal flora. In response to this subindication, Lishan's team developed LS-LBP-03 type 2 diabetes living biological drug strain group by combining multiple omics techniques such as immunity, metabolism, lipids and proteins. This strain group aims to restore the balance of the host's metabolic system and immune system by regulating the intestinal flora, alleviate the symptoms of insulin resistance, and is expected to achieve complete cure and reversal of type 2 diabetes. It is worth mentioning that this pipeline is the first innovative use of complete human immune organoid technology, which greatly improves the predictability of clinical trial results.